Effect of L carnitine supplementation on hemoglobin variability in maintenance hemodialysis patients

L carnitine and hemoglobin variability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202303871481191

Enrollment

126

Registered

2023-03-08

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

L carnitnine use

control group L carnitine not used

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age greater than 18 years receiving MHD three times per week

Exclusion criteria

Exclusion criteria: infection, hemoglobin disorders, malignancy, gastrointestinal bleeding, blood transfusions defore study onset

Design outcomes

Primary

Measure	Time frame
hemoglobin variability difference assessed by residual standard deviation, mean absolute change, coefficient of hemoglobin variation	—

Secondary

Measure	Time frame
predictors of Hb variability	—

Countries

Egypt

Contacts

Public Contactmohamed sary gharib

ain shams university faculty of medicine

mohamedsary@med.asu.edu.eg+201000322177

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026